We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| SurModics Inc | NASDAQ:SRDX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.89 | 13.96 | 36.74 | 0 | 09:09:56 |
From May 2023 to May 2024
By Dean Seal
Surmodics has received approval from the U.S. Food and Drug Administration for its SurVeil drug-coated balloon to be used in unblocking blood vessels.
The medical device company said Tuesday it can now market and sell the SurVeil DCB to U.S. physicians for percutaneous transluminal angioplasty of de novo or restenotic lesions in femoral and popliteal arteries that have reference vessel diameters of 4 millimeters to 7 millimeters.
Surmodics is set to receive a $27 million milestone payment from Abbott Laboratories, which has exclusive worldwide commercialization rights for the balloon. Surmodics will manufacture the device and earn revenue from product sales to Abbott, along with a share of profits from Abbott's third-party sales.
Chief Executive Gary Maharaj said the FDA's approval is a major milestone in the company's mission to help sufferers of peripheral artery disease.
The balloon received mark certification in the European Union in June 2020.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 20, 2023 07:08 ET (11:08 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year SurModics Chart |
1 Month SurModics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
